FHSS | Frontiers in Humanities and Social Sciences
← Back to Volume 5, Issue 10

Research on the Effect of Tongxinluo on Macrophage Foam Cell Formation

Mengshuang Ding, Zihao Wang, Hua Li, Yuxin Zhang
Vol. 5, No. 10, pp. 239-245, 2025 DOI: 10.54691/kwxdh543 October 16, 2025
Download PDF
Abstract.Objective: To investigate the effect of Tongxinluo (TXL) on the foam cell formation of macrophages (RAW264.7).  Methods: In vitro experiment: Cultured RAW264.7 mouse monocyte macrophages were divided into four groups: control group, model group, TXL treatment group, and DMSO group. A foam cell model was induced by incubating the macrophages with 50 μg/mL oxidized low-density lipoprotein (ox-LDL). The TXL treatment group was intervened with 100 μg/mL Tongxinluo. Lipid deposition within macrophages was observed using Oil Red O staining; cell proliferation activity was detected via a CCK-8 assay kit; and the levels of inflammatory factors (TNF-α, IL-1β, and IL-6) in the cell culture supernatant were measured by ELISA. Results: Compared with the control group, the model group exhibited a significant downregulation of macrophage proliferation activity, markedly increased lipid deposition, and a substantial increase in the release of inflammatory factors TNF-α, IL-1β, and IL-6 into the supernatant. In contrast to the model group, the TXL treatment group showed a significant upregulation of proliferation activity, markedly reduced lipid deposition, and a significant downregulation in the release of TNF-α, IL-1β, and IL-6. No significant changes in these indicators were observed in the solvent control (DMSO) group compared to the model group. Conclusion: Tongxinluo can significantly inhibit foam cell formation in macrophages and attenuate macrophage-mediated inflammatory injury.
Keywords. Tongxinluo; Macrophage foam cell formation; Inflammation; ox-LDL.
APA Citation Mengshuang Ding, Zihao Wang, Hua Li, Yuxin Zhang (2025). Research on the Effect of Tongxinluo on Macrophage Foam Cell Formation. Frontiers in Humanities and Social Sciences, 5(10), 239-245. https://doi.org/10.54691/kwxdh543

References

  1. Kuriakose D, Xiao Z. Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. Int J Mol Sci. 2020;21(20):7609.
  2. Yu HX. Correlation between homocysteine level and carotid atherosclerosis in elderly patients. Mod J Integr Tradit Chin West Med. 2020;29(04):391-394.
  3. Fang TF, Jiang M, Hu YW. Research progress on tissue-resident macrophages in atherosclerotic plaques. Chin J Cardiol. 2024;29(03):283-288.
  4. Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, Han X, Tang D, Chen R. Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules. 2018;8(3):80.
  5. Chistiakov DA, Melnichenko AA, Grechko AV, Myasoedova VA, Orekhov AN. Potential of anti-inflammatory agents for treatment of atherosclerosis. Exp Mol Pathol. 2018;104:114-124.
  6. Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. 2013;2013:152786.
  7. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986;46(6):705-716.
  8. Chen WQ, Zhong L, Zhang L, et al. Chinese medicine tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in a rabbit model. J Ethnopharmacol. 2009;124(1):103-110.
  9. Liu W, Li XX, Lin Q, et al. Systematic evaluation of Tongxinluo capsule combined with atorvastatin in the treatment of carotid atherosclerosis. Drug Eval Res. 2024;47(02):389-400.
  10. Wu S, Wu B, Liu M, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol. 2019;18(4):394-405.
  11. Bonati LH, Jansen O, de Borst GJ, et al. Management of atherosclerotic extracranial carotid artery stenosis. Lancet Neurol. 2022;21(3):273-283.
  12. Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524-533.
  13. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92(5):1355-1374.
  14. Bai B, Yang Y, Ji S, et al. MicroRNA‐302c‐3p inhibits endothelial cell pyroptosis via directly targeting NOD‐, LRR‐and pyrin domain‐containing protein 3 in atherosclerosis. J Cell Mol Med. 2021; 25(9): 4373-4386.
  15. Liu Q, Zhang D, Hu D, et al. The role of mitochondria in NLRP3 inflammasome activation. Mol Immunol. 2018;103:115-124.
  16. Fu J, Wu H. Structural mechanisms of NLRP3 inflammasome assembly and activation. Annu Rev Immunol. 2023;41(1):301-316.
  17. Kong P, Cui ZY, Huang XF, et al. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022;7(1):131.
  18. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13(10):709-721.
  19. Wu YL. Discussion on Collateral Disease Theory [M]. Beijing: China Science and Technology Press; 2010:670.
  20. Wu YL. Collaterology [M]. Beijing: China Press of Traditional Chinese Medicine; 2006:179-180.
  21. Li HR, Zhang X, Chang LP, et al. Research progress on anti-atherosclerosis effect of Tongxinluo Capsule. Chin Tradit Pat Med. 2016;38(2):386-391.